TY - BOOK AU - Howlader, N. AU - Noone, A. AU - Krapcho, M. PY - 2017 DA - 2017// TI - SEER cancer statistics review, 1975-2014 PB - National Cancer Institute CY - Bethesda ID - Howlader2017 ER - TY - JOUR AU - Goldstone, A. H. AU - Burnett, A. K. AU - Wheatley, K. AU - Smith, A. G. AU - Michael Hutchinson, R. AU - Clark, R. E. PY - 2001 DA - 2001// TI - Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial JO - Blood VL - 98 UR - https://doi.org/10.1182/blood.V98.5.1302 DO - 10.1182/blood.V98.5.1302 ID - Goldstone2001 ER - TY - JOUR AU - Anderson, J. E. AU - Kopecky, K. J. AU - Willman, C. L. PY - 2002 DA - 2002// TI - Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study JO - Blood VL - 100 UR - https://doi.org/10.1182/blood-2001-12-0354 DO - 10.1182/blood-2001-12-0354 ID - Anderson2002 ER - TY - JOUR AU - Ishizawa, J. AU - Kojima, K. AU - Hail, N. AU - Tabe, Y. AU - Andreeff, M. PY - 2015 DA - 2015// TI - Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein JO - Pharmacol Ther VL - 153 UR - https://doi.org/10.1016/j.pharmthera.2015.06.001 DO - 10.1016/j.pharmthera.2015.06.001 ID - Ishizawa2015 ER - TY - JOUR AU - Senapedis, W. T. AU - Baloglu, E. AU - Landesman, Y. PY - 2014 DA - 2014// TI - Clinical translation of nuclear export inhibitors in cancer JO - Semin Cancer Biol VL - 27 UR - https://doi.org/10.1016/j.semcancer.2014.04.005 DO - 10.1016/j.semcancer.2014.04.005 ID - Senapedis2014 ER - TY - STD TI - Das A, Wei G, Parikh K, Liu D. Selective inhibitors of nuclear export (SINE) in hematological malignancies. Exp Hematol Oncol. 2015;4:7. https://doi.org/10.1186/s40164-015-0002-5. ID - ref6 ER - TY - JOUR AU - Alexander, T. B. AU - Lacayo, N. J. AU - Choi, J. K. AU - Ribeiro, R. C. AU - Pui, C. H. AU - Rubnitz, J. E. PY - 2016 DA - 2016// TI - Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.67.5066 DO - 10.1200/JCO.2016.67.5066 ID - Alexander2016 ER - TY - JOUR AU - Kojima, K. AU - Kornblau, S. M. AU - Ruvolo, V. PY - 2013 DA - 2013// TI - Prognostic impact and targeting of CRM1 in acute myeloid leukemia JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2012-08-447581 DO - 10.1182/blood-2012-08-447581 ID - Kojima2013 ER - TY - JOUR AU - Parikh, K. AU - Cang, S. AU - Sekhri, A. AU - Liu, D. PY - 2014 DA - 2014// TI - Selective inhibitors of nuclear export (SINE)—a novel class of anti-cancer agents JO - J Hematol Oncol VL - 7 UR - https://doi.org/10.1186/s13045-014-0078-0 DO - 10.1186/s13045-014-0078-0 ID - Parikh2014 ER - TY - JOUR AU - Ranganathan, P. AU - Yu, X. AU - Na, C. PY - 2012 DA - 2012// TI - Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-04-423160 DO - 10.1182/blood-2012-04-423160 ID - Ranganathan2012 ER - TY - JOUR AU - Etchin, J. AU - Montero, J. AU - Berezovskaya, A. PY - 2016 DA - 2016// TI - Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice JO - Leukemia VL - 30 UR - https://doi.org/10.1038/leu.2015.194 DO - 10.1038/leu.2015.194 ID - Etchin2016 ER - TY - JOUR AU - Garzon, R. AU - Savona, M. AU - Baz, R. PY - 2017 DA - 2017// TI - A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia JO - Blood VL - 129 UR - https://doi.org/10.1182/blood-2016-11-750158 DO - 10.1182/blood-2016-11-750158 ID - Garzon2017 ER - TY - JOUR AU - Ranganathan, P. AU - Kashyap, T. AU - Yu, X. PY - 2016 DA - 2016// TI - XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase II to the nucleus JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2885 DO - 10.1158/1078-0432.CCR-15-2885 ID - Ranganathan2016 ER - TY - JOUR AU - Preisler, H. D. AU - Venugopal, P. AU - Gregory, S. A. PY - 2001 DA - 2001// TI - High remission rate in acute myeloblastic leukemia with only two days of chemotherapy JO - Leuk Lymphoma VL - 41 UR - https://doi.org/10.3109/10428190109057987 DO - 10.3109/10428190109057987 ID - Preisler2001 ER - TY - JOUR AU - Devemy, E. AU - Li, B. AU - Tao, M. PY - 2001 DA - 2001// TI - Poor prognosis acute myelogenous leukemia: 3—biological and molecular biological changes during remission induction therapy JO - Leuk Res VL - 25 UR - https://doi.org/10.1016/S0145-2126(01)00032-7 DO - 10.1016/S0145-2126(01)00032-7 ID - Devemy2001 ER - TY - JOUR AU - Larson, S. M. AU - Campbell, N. P. AU - Huo, D. PY - 2012 DA - 2012// TI - High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML) JO - Leuk Lymphoma VL - 53 UR - https://doi.org/10.3109/10428194.2011.621562 DO - 10.3109/10428194.2011.621562 ID - Larson2012 ER - TY - JOUR AU - Godley, L. A. AU - Njiaju, U. O. AU - Green, M. PY - 2010 DA - 2010// TI - Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant JO - Leuk Lymphoma VL - 51 UR - https://doi.org/10.3109/10428191003763468 DO - 10.3109/10428191003763468 ID - Godley2010 ER - TY - JOUR AU - Israyelyan, A. AU - Goldstein, L. AU - Tsai, W. PY - 2015 DA - 2015// TI - Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation JO - Bone Marrow Transpl VL - 50 UR - https://doi.org/10.1038/bmt.2014.209 DO - 10.1038/bmt.2014.209 ID - Israyelyan2015 ER - TY - JOUR AU - Miyawaki, S. AU - Hatsumi, N. AU - Tamaki, T. PY - 2010 DA - 2010// TI - Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia JO - Leuk Lymphoma VL - 51 UR - https://doi.org/10.3109/10428194.2010.507829 DO - 10.3109/10428194.2010.507829 ID - Miyawaki2010 ER - TY - JOUR AU - Le Tourneau, C. AU - Lee, J. J. AU - Siu, L. L. PY - 2009 DA - 2009// TI - Dose escalation methods in phase I cancer clinical trials JO - J Natl Cancer Inst VL - 101 UR - https://doi.org/10.1093/jnci/djp079 DO - 10.1093/jnci/djp079 ID - Le Tourneau2009 ER - TY - JOUR AU - Döhner, H. AU - Estey, E. H. AU - Amadori, S. PY - 2010 DA - 2010// TI - Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet JO - Blood VL - 115 UR - https://doi.org/10.1182/blood-2009-07-235358 DO - 10.1182/blood-2009-07-235358 ID - Döhner2010 ER - TY - JOUR AU - Cheson, B. D. AU - Bennett, J. M. AU - Kopecky, K. J. PY - 2003 DA - 2003// TI - Revised Recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.04.036 DO - 10.1200/JCO.2003.04.036 ID - Cheson2003 ER - TY - JOUR AU - Zhang, W. AU - Ishizawa, J. AU - Mu, H. AU - Daver, N. AU - Ruvolo, V. PY - 2015 DA - 2015// TI - Combinatorial targeting of XPO1 and FLT3-ITD exerts synergistic anti-tumor effects in FLT3-mutated acute myeloid leukemias JO - Blood VL - 126 ID - Zhang2015 ER - TY - JOUR AU - Nowicki, M. AU - Ostalska-Nowicka, D. AU - Mikowiak, B. PY - 2006 DA - 2006// TI - Prognostic significance of Ki67-negative blast cell clone in the high risk group of children treated for acute myeloid leukaemia JO - Folia Histochem Cytobiol VL - 44 ID - Nowicki2006 ER - TY - CHAP AU - Gurion, R. AU - Belnik-Plitman, Y. AU - Gafter-Gvili, A. ED - Raanani, P. PY - 2012 DA - 2012// TI - Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia BT - Cochrane database of systematic reviews PB - Sons, Ltd CY - Chichester ID - Gurion2012 ER - TY - JOUR AU - Dombret, H. AU - Chastang, C. AU - Fenaux, P. PY - 1995 DA - 1995// TI - A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia JO - N Engl J Med VL - 332 UR - https://doi.org/10.1056/NEJM199506223322504 DO - 10.1056/NEJM199506223322504 ID - Dombret1995 ER - TY - JOUR AU - Fiedler, W. AU - Heuser, M. AU - Chromik, J. PY - 2016 DA - 2016// TI - Phase II results of Ara-C and idarubicin in combination with the selective inhibitor of nuclear export (SINE) compound selinexor (KPT-330) in patients with relapsed or refractory AML JO - Blood VL - 128 ID - Fiedler2016 ER - TY - JOUR AU - Abdul Razak, A. R. AU - Mau-Soerensen, M. AU - Gabrail, N. Y. PY - 2016 DA - 2016// TI - First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.65.3949 DO - 10.1200/JCO.2015.65.3949 ID - Abdul Razak2016 ER - TY - JOUR AU - Kuruvilla, J. AU - Byrd, J. C. AU - Flynn, J. M. PY - 2014 DA - 2014// TI - The oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical activity in relapsed /refractory non Hodgkin’s lymphoma (NHL) JO - Blood VL - 124 ID - Kuruvilla2014 ER - TY - JOUR AU - Smith, L. A. AU - Cornelius, V. R. AU - Plummer, C. J. PY - 2010 DA - 2010// TI - Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials JO - BMC Cancer VL - 10 UR - https://doi.org/10.1186/1471-2407-10-337 DO - 10.1186/1471-2407-10-337 ID - Smith2010 ER - TY - JOUR AU - Herzig, R. H. AU - Hines, J. D. AU - Herzig, G. P. PY - 1987 DA - 1987// TI - Cerebellar toxicity with high-dose cytosine arabinoside JO - J Clin Oncol VL - 5 UR - https://doi.org/10.1200/JCO.1987.5.6.927 DO - 10.1200/JCO.1987.5.6.927 ID - Herzig1987 ER - TY - JOUR AU - Jolson, H. M. AU - Bosco, L. AU - Bufton, M. G. PY - 1992 DA - 1992// TI - Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine JO - J Natl Cancer Inst VL - 84 UR - https://doi.org/10.1093/jnci/84.7.500 DO - 10.1093/jnci/84.7.500 ID - Jolson1992 ER - TY - JOUR AU - Etchin, J. AU - Berezovskaya, A. AU - Conway, A. S. PY - 2016 DA - 2016// TI - KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells JO - Leukemia VL - 31 ID - Etchin2016 ER -